Fulgent Genetics presents FID-007 Phase 2 data at ASCO 2026 meeting

Fulgent presented updated data for FID-007 in combination with cetuximab for recurrent/metastatic head and neck cancer, showing 61.9% objective response rate and manageable safety profile as of April 16, 2026. The company plans to advance to Phase 3 studies, which could expand its therapeutic pipeline beyond its core laboratory services business.